Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Prescient Therapeutics Limited ( (AU:PTX) ) just unveiled an update.
Prescient Therapeutics Limited has announced the initiation of its first U.S. site for the Phase 2a clinical trial of PTX-100 at the VCU Massey Comprehensive Cancer Center, marking a significant milestone in the treatment of refractory/relapsed Cutaneous T-Cell Lymphoma (CTCL). This expansion into the U.S. complements the ongoing trials in Australia and represents a crucial step in broadening patient access to this innovative therapy, potentially strengthening Prescient’s position in the oncology market.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches to cancer, including targeted and cellular therapies. Their primary products include PTX-100, a first-in-class compound targeting cancer growth enzymes, and CellPryme technologies that enhance cell therapy performance.
Average Trading Volume: 997,562
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$33.82M
For a thorough assessment of PTX stock, go to TipRanks’ Stock Analysis page.